Subscribe to Medtronic
View Sample

FREE Email Newsletter

New Implantable Device Can Manipulate and Record Brain Activity

August 9, 2013 3:00 pm | by Massachusetts Institute of Technology | News | Comments

A new brain implant that can record neural activity while it simultaneously delivers electric current has been implanted into a patient for the first time. The new device from Medtronic, a Minneapolis-based medical device company, can also adjust its electrical output in response to the changing conditions of the brain.

Conflicting decisions and new tactics in Medtronic Infuse lawsuits

August 8, 2013 1:06 pm | by Mass Device | News | Comments

The battle over Medtronic's Infuse bone-growth protein continues to be a roller-coaster, with judges in 2 states issuing seemingly conflicting rulings about the validity of patient injury lawsuits against the Minnesota medical device giant and its troubled Infuse bone-growth protein.

Medtronic Provides Grant for Program Focused on Medical Devices for Developing Countries

July 24, 2013 10:48 am | by Johns Hopkins University | News | Comments

Medtronic, one of the world’s largest medical technology companies, has entered into an innovative partnership with The Johns Hopkins University, agreeing to provide $200,000 a year for up to three years and skilled mentoring to help biomedical engineering students design new healthcare solutions for underserved patients in developing countries.


Edwards Lifesciences goes after another set of Medtronic patents

July 16, 2013 1:35 pm | by Mass Device | News | Comments

Edwards Lifesciences wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic are invalid because they aren't specific enough. The patents cover nerve stimulation technology. Edwards and Medtronic have spent considerable time in courts around the world, each arguing that the other's transcatheter aortic valve implant infringes various patents.

Medtronic's insulin pump recall gets FDA's highest-risk label

July 15, 2013 9:59 am | by Mass Device | News | Comments

The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year. Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.

Medtronic prevails in bone mill antitrust suit filed by Lenox MacLaren Surgical

July 3, 2013 11:21 am | by Mass Device | News | Comments

Medtronic (NYSE:MDT) prevailed in an antitrust lawsuit filed over a bone mill made by Lenox MacLaren Surgical, with a federal judge ruling that Lenox misrepresented the size of the bone mill market and failed to adequately market its own device.

More hospitals settle Medtronic's Kyphon Medicare fraud cases

July 2, 2013 12:58 pm | by Mass Device | News | Comments

Some 55 U.S. hospitals agreed to pay a total of $34 million to settle U.S. Justice Dept. charges that they overcharged Medicare for Medtronic's (NYSE:MDT)'s kyphoplasty spine procedure, acquired in the $3.9 billion buyout of Kyphon in 2007, the Justice Dept. said today.

Integra LifeSciences recall affects Medtronic's Infuse kits

July 2, 2013 12:53 pm | by Mass Device | News | Comments

Minnesota medical device giant Medtronic (NYSE:MDT) confirmed today that it recalled certain of its already-troubled Infuse spinal fusion surgery kits after learning of possible contamination in sponges manufactured by Integra Lifesciences.  


Medtronic Issues Medical Device Notifications Regarding the SynchroMed® Implantable Infusion System

June 26, 2013 4:06 pm | by The Associated Press | News | Comments

In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable Infusion System.

Effects of DBS on Motor Symptoms of Parkinson's Disease

June 25, 2013 11:49 am | by Andrew Johnson | Videos | Comments

In November 2012 and February 2013, Andrew Johnson underwent a surgical procedure, Deep Brain Stimulation surgery, to help control his motor symptoms. This video represents his experience of how DBS has helped him. He is using a device from Medtronic.

Doctors Make Progress Toward 'Artificial Pancreas'

June 24, 2013 11:20 am | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

Doctors are reporting a major step toward an "artificial pancreas," a device that would constantly monitor blood sugar in people with diabetes and automatically supply insulin as needed. A key component of such a system—an insulin pump programmed to shut down if blood-sugar dips too low while people are sleeping—worked as intended in a three-month study of 247 patients.

ALRT's Internet-Based Glucose Monitoring Platform Compares Favorably with Medtronic's Continuous Glucose Monitoring System

June 24, 2013 8:18 am | by The Associated Press | News | Comments

This weekend, ALR Technologies announced at the American Diabetes Association meeting in Chicago that the A1c reduction in insulin-requiring patients with type 2 diabetes mellitus who managed their blood glucose using ALRT's Internet-Based Glucose Monitoring (IBGMS) platform, "Health-e-Connect", demonstrated comparable results to patients using Medtronic's "Guardian REAL-Time Continuous Glucose Monitoring System" (RT-CGM).

Medtronic Slips After Infuse Reviews Detailed

June 19, 2013 1:23 pm | by The Associated Press | News | Comments

Shares of Medtronic slipped Tuesday, a day after the medical device maker announced findings from independent reviews of studies of its Infuse bone graft. The Minneapolis company said the reviews, conducted through Yale University, concluded that clinical success rates with its Infuse product were equivalent to more traditional bone graft procedures in which bone is taken from the hip.


Medtronic Announces CE Mark of Its ReDuX(TM) Plier Instrument, an Innovative Device to Perform Osteotomies in Spinal Deformity Surgeries

June 13, 2013 2:06 am | by The Associated Press | News | Comments

Medtronic, Inc. has announced the CE Mark and the European launch of the ReDuX Plier, a new instrument specially designed for use during osteotomies.  With the launch of this first specially-designed surgical instrument in the spinal orthopaedic industry, physicians in the European community may now perform a more controlled osteotomy closure for people with a severe form of spinal curvature.

Medtronic Reaches Major Milestone in Clinical Program for 'IN.PACT Admiral' Drug-Eluting Balloon

June 3, 2013 7:06 am | by The Associated Press | News | Comments

Continuing to demonstrate its ongoing commitment to advancing interventional treatments of peripheral artery disease and the evidence to support their adoption, Medtronic, Inc. announced today that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's U.S. regulatory approval submission of the novel angioplasty device.

Medtronic's Endurant AAA Stent Graft Delivers Durable Outcomes for Abdominal Aortic Aneurysm Repair

May 31, 2013 10:06 am | by The Associated Press | News | Comments

The Endurant AAA stent graft system from Medtronic, Inc. continues to distinguish itself, with new data on the market-leading device for the endovascular repair of abdominal aortic aneurysms demonstrating durable clinical performance through three years of patient follow-up.

Medtronic Garners FDA Approval for Stent Graft System

May 30, 2013 11:01 am | by Medtronic Inc. | News | Comments

Medtronic, Inc. (NYSE: MDT) is expanding its market-leading portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA’s 510(k) clearance for the Sentrant Introducer Sheath.

Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity Renal Denervation System for Treatment-Resistant Hypertension

May 23, 2013 6:06 am | by The Associated Press | News | Comments

Medtronic, Inc., today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous system and help regulate blood pressure.

Medtronic Finds TAVI with CoreValve System Cost Effective for Treating Patients with Severe Aortic Stenosis

May 21, 2013 4:06 am | by The Associated Press | News | Comments

Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical management. Presented at EuroPCR 2013, the United Kingdom-based analysis compared the "real world" Medtronic CoreValve ADVANCE study to the medical management cohort of the PARTNER B study.

Medtronic Receives 'CE' Mark for 'Export Advance' Aspiration Catheter

May 20, 2013 7:06 am | by The Associated Press | News | Comments

Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark and will soon be launched in Europe and other international markets.

Biventricular Pacing Reduces Symptoms and Improves Quality-of-Life

May 13, 2013 9:52 am | by Medtronic | News | Comments

Medtronic has announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in a subset of heart failure patients.

Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring

May 10, 2013 4:06 pm | by The Associated Press | News | Comments

MINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a...

Medtronic Issues Statement on iPad Interference Study

May 10, 2013 11:02 am | by Medtronic | News | Comments

Medtronic's current internal analysis and testing shows iPad technology presents no risk of electromagnetic interference with Medtronic implantable cardiac rhythm devices when used per manufacturer's instructions. However, as a precaution, patients implanted with a pacemaker or ICD are advised to follow Apple and Medtronic labeling recommendations and maintain a distance of six inches between the iPad and implanted device.

Medical Device Global Labeling Strategies Conference

May 9, 2013 2:07 pm | by MDT Staff | Events

Gain best practices in overcoming international labeling challenges at the Medical Device Global Labeling Strategies Conference, July 24-25, 2013 in Minneapolis, MN. This premier marcus evans event will bring together leading medical device labeling professionals to discuss how to successfully create a label on both a national and international scale.

Medtronic Announces FDA Approval of New Portfolio Of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-Defibrillators

May 6, 2013 10:18 am | by Medtronic | News | Comments

Medtronic, Inc. has announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva® portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibrillators (ICD).

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.